Serum resistin as a potential biomarker for stratifying the severity of coronary heart disease: a network meta-analysis - Scorecard - MDSpire

Serum resistin as a potential biomarker for stratifying the severity of coronary heart disease: a network meta-analysis

  • By

  • Yicheng Ling

  • Mengyao Wei

  • Jiapeng Luo

  • Tianxiang Gu

  • Xuan Jiang

  • May 28, 2026

  • 0 min

Share

Clinical Scorecard: Evaluating Serum Resistin Levels as a Potential Indicator for Assessing Coronary Heart Disease Severity: A Network Meta-Analysis

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with varying severity of CHD, including healthy controls, stable CHD, acute coronary syndrome (ACS), and acute myocardial infarction (AMI)
Care Setting

Key Highlights

  • additional_info

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Clinical Best Practices

          • standardization

          Related Resources & Content

          Original Source(s)

          Serum resistin as a potential biomarker for stratifying the severity of coronary heart disease: a network meta-analysis

          • by Yicheng Ling, Mengyao Wei, Jiapeng Luo, Tianxiang Gu, Xuan Jiang

          • May 28, 2026

          Related Content

          Utilizing Optical Coherence Tomography Angiography and Optical Coherence Tomography for the Prediction of Polyvascular Disease

          Hospital Prices Posted. Few Patients Look.

          Federal rules require hospitals to post prices so patients can shop. Instead, insurers and providers use the data to negotiate what they get paid.

          AI Scribes: Efficiency for Whom?

          Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.